
Home » Pipeline
Pipeline
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
MiNa Therapeutics | MTL-CEBPA in combination with Keytruda (pembrolizumab) | advanced solid tumors | initiation and first patient treated in phase 1/1b trial |
TargoVax SA | ONCOS-102 in combination with Keytruda (pembrolizumab) | advanced anti-PD1 checkpoint inhibitor (CPI) refractory melanoma | patient enrollment completed in phase 1 trial |
HUYA Bioscience International | HBI-3000 | cardioversion of atrial fibrillation | completion of phase 1 trial |
Dynacure | DYN101 | myotubular and centronuclear myopathies | first patient dosed in phase 1/2 trial |
Allergan plc Editas Medicine |
AGN-151587 (EDIT-101) | Leber congenital amaurosis 10 (LCA10) | first patient dosed in phase 1/2 trial |
Arrowhead Pharma | ARO-HSD | patients with NASH or suspected NASH | first patients dosed in phase 1/2 trial |
DiscGenics | IDCT, allogeneic, injectable discogenic cell therapy | degenerative disc disease | completed enrollment in phase 1/2 trial |
Novus Therapeutics | OP0201 | pediatrics with acute otitis media | completed enrollment in phase 2a trial |
VBI Vaccines | VBI-1901 in combination with either GM-CSF or AS01B, (GlaxoSmithKline) | recurrent GBM | first patient dosed in the second study arm of phase 2a trial |
Innovent Biologics | IBI375 (pemigatinib) | advanced cholangiocarcinoma with FGFR2 fusions or rearrangements | first patients dosed in phase 2 trial |
Neuraly | NLY01 | Parkinson’s disease | first patient dosed in phase 2 trial |
Moderna | mRNA-1647 | cytomegalovirus | completed enrollment in phase 2 trial |
American BriVision | ABV-1505 | adult attention-deficit hyperactivity disorder | initiation of phase 2 trial |
EpicentRx | AIM-001 | tumors | IND approved by FDA |
Prevail Therapeutics | PR006 | frontotemporal dementia patients with GRN mutation | IND approved by FDA |
Ayala Pharmaceuticals | AL101 | recurrent or metastatic adenoid cystic carcinoma | Fast Track designation granted by FDA |
Genentech | Esbriet (pirfenidone) | adults with unclassifiable interstitial lung disease | Breakthrough Therapy Designation granted by FDA |
Sanofi | Sarclisa (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) | adults with multiple myeloma who have had two previous therapies including lenalidomide and a protease inhibitor | approved by the FDA |